Subject Index, 1983
Vol. 33, Nos. 1–6

A

Acromegaly
And pituitary tumors, 226–227

Adair, Frank E., tribute to (letter), 61

Adenocarcinoma, 237–241
In esophageal cancer, 268
Of unknown origin, 237–241
Diagnosis of, 237–239
Incidence of, 239
Prognosis and treatment of, 240
Survival rates for, 240

Antibodies
And cancer (letter), 189–190

Antineoplastic agents
Safety and risks in administration of, 258–263

Antineoplastons (unproven methods), 57–59

B

Beatson, George Thomas
Biography of, 105–107

Biographies
Beatson, George Thomas, 105–107
Cheek, J. Harold, 242–243

Bladder cancer
Death rates for, 9, 15, 17
Incidence of, 9, 16, 313
Mortality of, 11
Percent by stage, 23
In reproductive years, 197
Survival rates for, 22, 25

Bone cancer
Death rates for, 17
Incidence of, 16, 24
Mortality rates for, 11
In reproductive years, 197

Brain and central nervous system cancer
Brain metastasis from esophageal carcinoma (case report), 164–166; (letter), 319
Incidence of, 164–165
Treatment of, 166
Death rates for, 17
Incidence of, 16, 24, 313
Mortality rates for, 11
In pregnancy, 206
In reproductive years, 197
Survival rates for, 25

Breast cancer, 26–39, 105–121
Beatson, George Thomas and bilateral oophorectomy (classic), 105–121
As cause of death (letter), 192
Death rates for, 9, 14, 17, 19, 21
Incidence of, 9, 16, 18, 199, 313
Massachusetts law concerning (letters), 191, 376
Mortality rates for, 11
Percent by stage, 23
In pregnancy, 194–198, 211, 242–251
And prostaglandins, 327–329
Screening tests for, 26–39
Survival rates for, 22, 25, 69
Treatment of, 69, 105–121

C

Cancer, during pregnancy, 194–214, 242–251

Adrenal tumors, 208–209, 211
Bone and joint cancer, 197, 211
Breast cancer, 194–198, 211; (classic), 242–251
Central nervous system tumors, 197, 206
Colorectal cancer, 211
Eye cancer, 197
Gastrointestinal cancer, 197, 201–203, 211
Genital cancer, 198–201
Cervical cancer, 198–200
Endometrial cancer, 200
Ovarian cancer, 201, 211
Vaginal cancer, 201
Vulvar cancer, 200–201
Hepatic carcinoma, 211
Incidence of, 194–195
Lymphoma and leukemia, 197, 204–206, 211
Malignant melanoma, 197, 203–204, 211
Oral cancer, 197
Pancreatic cancer, 209–210
Respiratory cancer, 197, 211
Risk of metastasis to fetus, 210–211
Soft tissue sarcoma, 197, 207–208
Thyroid cancer, 197, 206–207
Urinary cancer, 197

Cancer-prone personalities
Methodology and theory of, 145–153

Carcinogens
Cancer risks of medical treatment (letter), 62–64
Occupational risk factors of, 74
Prostaglandins as, 322, 327–328
Risks of handling chemotherapeutic agents, 258–263

Case reports
Brain metastasis from esophageal carcinoma, 164–166
Granulocytic sarcoma of the peritoneum, 40–43
Metastatic chemodectoma with multiple nodular lesions, 98–99
Metastatic islet cell carcinoma, 167–171

Cervical cancer
Incidence of, 199, 313
In pregnancy, 198–200

Cheek, J. Harold
Biography of, 242–243

Chemodectoma, metastatic
(case report), 98–99

Chemotherapy
In adenocarcinoma, 240
In esophageal carcinoma, 269–270, 272, 274
In head and neck cancer, 139–144
And hyperthermia, 53–54
In islet cell carcinoma, 168
In lung cancer, 80–84
In peripheral nervous system tumors, 297–298
And prostaglandins, 322, 327
Safety in intravenous administration of, 258–263
In testicular cancer, 102–104

Classics in oncology
Cancer incidence in Mormons and non-Mormons in Utah, 309–316
On lymphoepithelial tumors (Schmincke tumors), 172–179
On the treatment of inoperable cases of carcinoma of the mamma, 108–121
Survey of current opinions concerning carcinoma of the breast occurring during pregnancy, 244–251

Colon and rectum cancer, 333–369
ACS
Colorectal Health Check Program (CHEC), 368–369
Detection guidelines, 366–367
Death rates for, 9, 14–15, 17, 19–20
Detection demonstration project, 344–358
Comparison of rectal examination with six-slide test, 351, 355
Diagnosis and treatment, 347–350
Education of medical and clerical staff, 348, 350
Methodology, 345–350
Occult blood testing, 344–358
Proctosigmoidoscopy, 345, 348, 350
Pros and cons of centralized detection team, 353, 356–357
Results, 350–357
Subject recruitment and compliance, 346–348, 350
Examination for (letter), 191
Incidence of, 9, 16, 18, 313, 345, 366
Mortality rates for, 11
Percent by stage, 23
In pregnancy, 197, 201–203, 211
Public attitude survey about, 359–365
Risks and benefits of mass screening with stool guaiac test, 333–343
Program protocol, 334–335
Public response, 335, 337
Results, 335–343
Survival rates for, 22, 25, 366
Symptoms of, 366

Craniopharyngiomas
(See also, Pituitary tumors)
Incidence of, 227

D

Dimethyl sulfoxide (DMSO) (unproven methods), 122–125

E

Editorial
A minute of your time, 307–308
Cancer prevention study shows decline in cigarette smoking, 307
Great American Smokeout, 307
US Surgeon General's report on smoking, 307–308

Endometrial cancer
In pregnancy, 200

Esophageal cancer, 264–281
Brain metastasis from (case report), 164–166; (letter), 319
Death rates for, 15, 17
Diagnosis by endoscopy, 266
Incidence of, 16, 264–265, 267–269, 313
Mortality rates for, 273, 277
Percent by stage, 23
Survival rates for, 25, 265, 270, 272–278
Treatment of, 269–278
Types of, 267–269

Esthesioneuroblastoma, 154–159
Death rates for, 155–156
Incidence rates of, 154, 156
Signs and symptoms of, 154
Staging of, 157
Survival rates for, 155–158
Treatment of, 154–156, 158

Eye cancer
Death rates for, 17
Incidence of, 16
In reproductive years, 197
Retinoblastoma, incidence of, 24; (letter), 317–319

G

Gestational trophoblastic neoplasia
Incidence of (letter), 61–62

Granulocytic sarcoma
In the peritoneum (case report), 41–43

"Greek Cancer Cure" (unproven methods), 252–254

H

Head and neck cancer, 130–144
Adjuvant chemotherapy in, 139–144
Toxicity in, 142
AJC staging of, 130–133
In larynx, 130, 132–133
In oral cavity, 130–131, 133
In paranasal sinuses, 130, 132–133
In pharynx, 130–131, 133
Esthesioneuroblastoma, 154–159
Etiology of, 139
History of nasopharyngeal cancer, 180–185
Radiation therapy in, 134–139
Surgery in, 134–139
Survival rates for, 136–137

Hodgkin's disease
Death rates for, 17
Incidence of, 16
Mortality rates for, 11
In pregnancy, 205
Survival rates for, 22, 25

Hospice
Concept of (letters), 60, 191–192

Hypercalcemia
And prostaglandins, 328

Hyperthermia, 44–56
As adjunct to surgical therapy, 52
Chemotherapy and, 53–54
History of, 44–45; (letter), 126
Methodology of, 45–48
Radiation therapy and, 52–53
And statistics (letter), 190
Toxicity in, 51–52

I

Interview
Oncogenes, 300–306

Iscador (unproven methods), 186–188

K

Kidney cancer
Death rates for, 17
Incidence of, 16, 24
Mortality rates for, 11
Percent by stage, 23
And prostaglandins, 328
Survival rates for, 22, 25

L

Larynx cancer
Death rates for, 17
Incidence of, 16, 313
Radiation treatment of, 68
Staging of, 130, 132–133
Survival rates for, 22, 25

Leukemia
Death rates for, 9, 14–15, 17, 19, 21
And granulocytic sarcoma, 40–43
Incidence of, 9, 16, 18, 24
Mortality rates for, 11
In pregnancy, 197, 204–206, 211
Survival rates for, 22, 25

Liver cancer
Death rates for, 14–15
Incidence of, 24
Percent by stage, 23

Lung cancer, 74–86
AJC staging of, 76, 78–80
Chemotherapy for, 80–84
Current concepts and prospects for, 74–86
Death rates for, 9, 14–15, 17, 19–20, 74
Detection of, 76
Incidence of, 9, 16, 18, 25, 213
Morphology of, 74–76
Mortality rates for, 11
Percent by stage, 23
In pregnancy, 197, 211
And prostaglandins, 327
Survival rates for, 22, 25, 80–84
Treatment of, 80–84

Lymphomas
Death rates for, 9, 17
Incidence of, 9, 16, 24
In pregnancy, 197, 204–206, 211
Survival rates for, 25

M

Mammography
Age guidelines (letter), 60
Background statement and 1983 update of cancer-related checkup guidelines for breast cancer detection in asymptomatic women age 40 to 49, 255
Efficacy of, 26–29, 32–37

Melanoma, malignant, 160–163
Detection of, 160–163
Dissection for (letter), 126–127
Incidence in females, 16, 199
Mortality rates for, 11, 17
Percent by stage (skin), 23
In pregnancy, 197, 203–204, 211
Radiation treatment of, 70
Signs and symptoms of, 160–162
Survival rates for (skin), 25

Multiple myeloma
Death rates for, 17
Incidence of, 16
Survival rates for, 22

N

Nasopharyngeal cancer, 180–185
AJC staging of, 130–133
History of, 180–185

O

Oncogenes (interview), 300–306
History of, 302–304, 306
Morphology of, 300, 302–306

Opinion
Is there a cancer-prone personality?, 145–153

Oral cancer
Death rates for, 9, 17, 19–20
Incidence of, 9, 16, 18, 25, 313
Percent by stage, 23
In pregnancy, 197
Survival rates for, 25

Ovarian cancer
Death rates for, 9, 14, 17
Incidence of, 9, 16, 313
Mortality rates for, 11
Percent by stage, 23
In pregnancy, 201, 211
Survival rates for, 22

P

Pancreatic cancer
Death rates for, 9, 14–15, 17, 19
Incidence of, 9, 16, 18, 169, 313
Mortality rates for, 11
Percent by stage, 23
In pregnancy, 209–210

Pancreatic islet cell carcinoma (case report), 167–171
Chemotherapy for, 168
Incidence of, 169

Penile cancer
In uncircumcised male (letter), 319–320

Peripheral nervous system tumors, 282–299
Diagnosis, 282, 293–294
Incidence, 282, 286, 288
Multiple neurofibromatosis (von Recklinghausen's disease), 286–294, 298–299
Incidence of, 286, 288
Morphology of, 286–291
In pregnancy, 288–291
Survival rates for, 298–299
Treatment of, 291–292, 298
In soft somatic tissues, 282–299
Benign, 284–292, 299
Malignant, 292–299
Nonmalignant lesions, 282–284
Survival rates for, 298–299
Treatment, 283, 285, 291–292, 294–299

Pituitary tumors, 215–236
Acromegaly and, 226–227
Clinical features of, 218–227
Diagnosis and therapy, 215–231
With CT scan, 215–219, 222, 226
Use of dopamine agonists in, 228–231
With surgery, 226–231
Metastatic, 227
Negative feedback, 227
Types of, 227–228

Prostaglandins, 322–332
As adjuvant therapy to chemotherapy and radiation, 328
Breast cancer and, 327–328
And chemical carcinogens, 327
Arachidonic acid cascade, 324, 327
Hypercalcemia and, 328
Immune responses and, 328
Lung cancer and, 327
Metastasis inhibition with, 328–329
In prevention and treatment of cancer, 322–332
Prostate cancer and, 328
Renal cancer and, 328
Structure of, 322–326
Tumor produced, 327–328

Prostate cancer
Death rates for, 9, 15, 17, 19, 21
Incidence of, 9, 16, 18, 313
Mortality rates for, 11
Percent by stage, 23
And prostaglandins, 327
Radiation treatment of, 69
Survival rates for, 22, 25

R

Radiation therapy, 66–73
In adenocarcinoma, 240
In brain metastasis, 166
In breast cancer, 69
Changing role of cancer management, 66–73
In esophageal carcinoma, 266–267, 269–270, 272
In head and neck cancer, 134–138, 154–155, 158
History of, 66–68
In hyperthermia, 47, 52–53
In larynx cancer, 68
In lung cancer, 82–83
In malignant melanoma, 70
Patterns of Care Study guidelines, 67–73
In peripheral nervous system tumors, 296–298
In pituitary tumors, 226–231
And prostaglandins, 328
In prostate cancer, 69
In testicular cancer, 102, 104
In thyroid cancer, 90, 93–97

Retinoblastoma (letter), 317–319
Incidence of, 317–319

S

Schmincke, Alexander (classic), 172–179

Screening
For breast cancer, 26–39
For colorectal cancer, 333–358, 366–367
For lung cancer, 76, 80
For melanoma, 160–163
For pituitary tumors, 215–236

Skin cancer
(See also Melanoma, malignant)
Death rates for, 9, 17, 21
Incidence of, 9, 16, 25
Mortality of, 11
Percent by stage, 23
In pregnancy, 203–204, 211
In reproductive years, 197
Survival rates for, 25

Small intestine cancer
Death rates for, 17
Incidence of, 16

Statistics, cancer, 9–25
(See also, specific sites)
ACS estimates of cancer cases and deaths, 2–8

Death rates
By geographic location, 19–21
By leading causes among children, 24
By site and sex, 9, 14–15, 17
Incidence
By geographic location, 18
By site and sex, 9, 16
By site for children, 24
By stage at diagnosis, 23
Mortality rates
By leading cancer sites, 11
By leading causes, 10
Leading causes by age and sex, 12–13
Survival rates
By site and race, 22, 25
Trends, 25

Stomach cancer
Death rates for, 14–15, 17, 19, 21
Incidence of, 16, 18, 313
Mortality rates for, 11
Percent by stage, 23
Survival rates for, 22, 25

Stool guaiac test (fecal occult blood), 333–343
ACS detection guidelines concerning, 366–367
In bowel cancer detection demonstration project, 344–358
And public attitudes, 359–365
Risks and benefits of mass screening, 333–343

Surgery
In adenocarcinoma, 240
As adjuvant to hyperthermia, 52
In breast cancer during pregnancy, 244–251
In esophageal carcinoma, 269–278
In head and neck cancer, 134–137, 154–156, 158
In lung cancer, 80–84
In peripheral nervous system tumors, 283–286, 290–299
In pituitary tumors, 227–231
In testicular cancer, 102–104
In thyroid cancer, 88, 90–97

Sympathetic nervous system cancer
Incidence of, 24

T

Testicular cancer, 100–104
Death rates for, 17
Incidence of, 16, 100
Morphology of, 101
Mortality rates for, 11
Staging and classification of, 100–102
Treatment of, 100, 102–104

Thermography
Efficacy of, 26–27, 30–37, 370–376 (letters)

Thyroid cancer, 87–97
AJC staging and classification of, 87–88
Death rates for, 17
Incidence of, 16
Percent by stage, 23
In pregnancy, 206–207
In reproductive years, 197
Survival rates for, 25, 88–97
Treatment of, 88, 90–97

U

Unproven methods of cancer management
Alivizatos, Hariton ("Greek Cancer Cure"), 252–254
Antineoplastons, 57–59
Dimethyl sulfoxide (DMSO), 122–125
Iscador, 186–188

Uterine cancer
Death rates for, 9, 14, 17, 19, 21
Incidence of, 9, 16, 18, 313
Mortality rates for, 11
Percent by stage, 23
Survival rates for, 22, 25

V

Vaginal cancer
In pregnancy, 201

Von Recklinghausen's disease
(See multiple neurofibromatosis under peripheral nervous system tumors)

Vulvar cancer
In pregnancy, 200–201

Author Index, 1983
Vol. 33, Nos. 1–6

A

Abcarian H, 344–358
Andrews W, 87–97
Ariel IM, 282–299
Averbuch SD, 164–166

B

Baker HW, 130–133
Beatson GT, 108–121
Blinder MA, 164–166
Bosl GJ, 139–144
Bottiglieri NG, 368–369
Brady LW, 66–73
Bright-Asare P, 344–358

C

Cheek JH, 244–251
Cook DM, 215–236
Cortese DA, 74–86

D

Day CL, 160–163
Donegan WL, 194–214

E

Ellis FH Jr, 264–281

F

Farber M, 344–358
Farr HW, 134–138
Feghali J, 154–159
Fink DJ, 366–367
Fitzpatrick J, 344–358
Fitzpatrick TB, 160–163
Fontana RS, 74–86
Frank R, 258–263

G

Gardner JW, 309–316

H

Hodgkin JE, 98–99
Hoffman A, 344–358
Holleb AI, 307–308

J

Jett JR, 74–86
Jones RB, 258–263

K

Kaiser DL, 87–97
Karmali RA, 322–332
Klauber MR, 309–316
Kopf AW, 160–163

L

Lidow E, 344–358
Lubera JA, 2–8
Lyon JL, 309–316

M

Maher ML, 333–343
Mass T, 258–263
Miksanek T, 40–43

Molnar ZV, 40–43
Morton DL, 44–56
Moskowitz M, 26–39
Muir CS, 180–185
Murphy GP, 100–104

N

Neilan BA, 237–241

O

Orsay C, 344–358

P

Petani C, 344–358

R

Reyes CV, 40–43

S

Schmincke A, 172–179
Semkiw Z, 40–43
Shah JP, 154–159
Shansky R, 344–358
Silverberg E, 2–8, 9–25
Smart CR, 309–316
Sober AJ, 160–163
Soeprono FF, 98–99
Stockwell S, 105–107, 242–243
Storm FK, 44–56
Summerville J, 344–358
Sylvester J, 333–343

V

Vikram B, 134–138

W

Wanebo HJ, 87–97
Weinberg RA, 300–306
Weitberg AB, 167–171
Weitzman SA, 167–171
Wellisch DK, 145–153
Winchester DP, 333–343

Y

Yager J, 145–153
Young Q, 344–358

Z

Zai D, 344–358